ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1609

Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials

Stephen Hall1, Peter Nash2, Maureen Rischmueller3, Zirke Wiid4, David Witcombe5, David Gruben6, Ryan DeMasi7 and Tatjana Lukic7, 1Cabrini Medical Centre, Monash University, Melbourne, Australia, 2University of Queensland, Brisbane, Australia, 3The Queen Elizabeth Hospital, Adelaide, Australia, 4Pfizer Australia, Sydney, Australia, 5Pfizer Australia, Sydney, NSW, Australia, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Tofacitinib

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis of data from Phase 3 studies investigated the efficacy of tofacitinib in patients (pts) according to RA duration (early vs late).

Methods: Pts from 5 placebo-controlled Phase 3 studies (ORAL Step [NCT00960440]; ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307], ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]) of tofacitinib as monotherapy or with background DMARDs were included. This analysis included pts who were inadequate responders (IR) to ≥1 DMARDs randomized to tofacitinib 5 mg or 10 mg BID, placebo or adalimumab (ORAL Standard); results for tofacitinib 5 mg BID are presented. Pts were evaluated according to RA duration at baseline (years [yr]): ≤1 vs >1; ≤2 vs >2; ≤3 vs >3. For each subset pair, at Month 3 and Month 6 we evaluated proportions of pts achieving ACR20/50/70 response, Disease Activity Score (ESR) (DAS 28-4[ESR]) <2.6 (remission), DAS28-4(ESR) ≤3.2 (low disease activity), HAQ-DI minimal clinically important difference (MCID) ≥0.22, 0.30, 0.50, and 0.80, and mean changes from baseline in DAS28-4(ESR) and HAQ-DI scores. Odds ratios (ORs [for rates]) and mean differences (for change from baseline) were calculated with corresponding 95% CIs, and 2-sided p values (‘>’ category as reference). Non-responder imputation (NRI) was applied for rates. Pts meeting criteria for rescue (failed to achieve ≥20% improvement from baseline at Month 3 in applicable studies) had NRI applied or were excluded from mean change analyses at Month 6.

Results: At Month 3, significantly greater OR for ACR20, ACR50, HAQ-DI MCID ≥0.22, and ≥0.30 were shown for ≤1 vs >1 yr and ≤2 vs >2 yr subsets (Figure). HAQ-DI MCID ≥0.50 and ≥0.80 were significantly greater for ≤1 vs >1 yr, ≤2 vs >2 yr, and ≤3 vs >3 yr subsets. For all other efficacy outcomes, ORs were not statistically significant between subsets at Month 3. Mean changes from baseline in DAS28-4(ESR) were significantly greater for ≤1 vs >1 yr and ≤2 vs >2 yr subsets at Month 3 (Table). Mean changes from baseline in HAQ-DI at Month 3 was significantly greater for ≤1 vs >1 yr, ≤2 vs >2 yr, and ≤3 vs >3 yr subsets. In general, higher responses were seen at Month 3 in pts with early vs late RA disease duration.

Conclusion: In this analysis, a trend was observed indicating that DMARD-IR pts with earlier disease duration at treatment initiation respond better to tofacitinib 5 mg BID than pts with late disease duration. Results suggest that initiating tofacitinib earlier in the disease may yield greater treatment response and thereby reduce the time pts experience active disease.


Disclosure: S. Hall, Pfizer Inc, Celgene, Roche, AbbVie, Eli-Lilly, Janssen, 5; P. Nash, None; M. Rischmueller, None; Z. Wiid, Pfizer Inc, 1,Pfizer Inc, 3; D. Witcombe, Pfizer Inc, 1,Pfizer Inc, 3; D. Gruben, Pfizer Inc, 1,Pfizer Inc, 3; R. DeMasi, Pfizer Inc, 1,Pfizer Inc, 3; T. Lukic, Pfizer Inc, 1,Pfizer Inc, 3.

To cite this abstract in AMA style:

Hall S, Nash P, Rischmueller M, Wiid Z, Witcombe D, Gruben D, DeMasi R, Lukic T. Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-tofacitinib-in-patients-who-are-inadequate-responders-to-disease-modifying-antirheumatic-drugs-according-to-early-versus-late-duration-of-rheumatoid-arthritis-post-hoc-analysis-of-data-fr/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-tofacitinib-in-patients-who-are-inadequate-responders-to-disease-modifying-antirheumatic-drugs-according-to-early-versus-late-duration-of-rheumatoid-arthritis-post-hoc-analysis-of-data-fr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.